BRIDGEWATER, N.J., Dec. 18, 2017 — Valeritas Holdings, Inc. (NASDAQ:VLRX), a medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies, announced today that John Timberlake, President and Chief Executive Officer of Valeritas, will commemorate the Company’s recent listing on the Nasdaq Capital Market by ringing the Nasdaq Closing Bell. Joining members of the Company's management team during this ceremony and ringing the bell with Mr. Timberlake will be Joe Dougherty, an individual with Type 2 diabetes who wears Valeritas’ V-Go® Wearable Insulin Device daily to better manage his condition.
“This has been an exciting and productive year for Valeritas,” said Mr. Timberlake. “V-Go, a simple to use, wearable insulin delivery device worn like a patch is proven technology that can help replace multiple daily insulin injections for the two million Americans with type 2 diabetes currently asked to take multiple shots every day.” Where: Nasdaq MarketSite – 4 Times Square – 43rd & Broadway – Broadcast StudioWhen: Tuesday, December 19, 2017 – 3:45 p.m. to 4:00 p.m. ETA live webcast of the ceremony will be available starting at 3:45 pm at: https://new.livestream.com/nasdaq/live or http://www.nasdaq.com/about/marketsitetowervideo.asx.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that is worn like a patch. V-Go enables patients to administer a continuous preset basal rate of insulin over 24 hours and it also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Marlborough, Massachusetts.More information is available at www.valeritas.com and our Twitter feed @Valeritas_US, www.twitter.com/Valeritas_US.Forward-Looking StatementsThis press release may contain forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to Valeritas technologies, business and product development plans and market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue Valeritas’ business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize the V-Go® Wearable Insulin Delivery device with limited resources, competition in the industry in which Valeritas operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and Valeritas assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents Valeritas files with the SEC available at www.sec.gov.Investor Contacts:
Lynn Pieper Lewis or Greg Chodaczek
[email protected]Media Contact:
Knight Marketing Communications, Ltd.
Latest posts by Brad Bennett (see all)
- New Hope for Adoptees Searching for Biological Family - February 24, 2018
- Free People to Open in Palm Springs, California - February 24, 2018
- Level 3 Construction Completes $4M Renovation at the Holiday Inn ExpressÂ® West Los Angeles - February 24, 2018